Recent research indicates a reduction in apoF levels in individuals with hepatic steatosis, with decreased hepatic apoF expression correlating with an atherogenic lipid profile characterized by elevated levels of triglycerides, non-HDL cholesterol, and diminished levels of HDL-cholesterol [21]. The gene discussed is APOF; the disease is fatty liver disease.